

IDS Mail Date: 12/12/2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10561639
	Filing Date	2005-12-20
	First Named Inventor	Karsten WASSERMANN
	Art Unit	1614
	Examiner Name	Zhang, Nancy L.
	Attorney Docket Number	DRF 3.3-054

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
WW	1	6133293		2000-10-17	Ikeda, et al.	
	2	6150383		2000-11-21	Ikeda, et al.	
	3	6153632		2000-11-28	Rieveley	
	4	6156773		2000-12-05	Ikeda, et al.	
	5	6169099	B1	2001-01-02	Ikeda, et al.	
	6	6172089	B1	2001-01-09	Ikeda, et al.	
	7	6211205	B1	2001-04-03	Ikeda, et al.	
↓	8	6211206	B1	2001-04-03	Ikeda, et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10561639
Filing Date	2005-12-20
First Named Inventor	Karsten WASSERMANN
Art Unit	1614
Examiner Name	Zhang, Nancy L.
Attorney Docket Number	DRF 3.3-054

1/WW/	9	6211207	B1	2001-04-03	Ikeda, et al.	
	10	6214848	B1	2001-04-10	Ikeda, et al.	
	11	6218409	B1	2001-04-17	Ikeda, et al.	
	12	6232330	B1	2001-05-15	Ikeda, et al.	
	13	6239153	B1	2001-05-29	Ikeda, et al.	
	14	6251924	B1	2001-06-26	Ikeda, et al.	
	15	6274605	B1	2001-08-14	Ikeda, et al.	
	16	6277869	B1	2001-08-21	Ikeda, et al.	
	17	6288090	B1	2001-09-11	Ikeda, et al.	
	18	6303640	B1	2001-10-16	Ikeda, et al.	
↓	19	6323225	B1	2001-11-27	Ikeda, et al.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>( Not for submission under 37 CFR 1.99)</small>	Application Number	10561639
	Filing Date	2005-12-20
	First Named Inventor	Karsten WASSERMANN
	Art Unit	1614
	Examiner Name	Zhang, Nancy L.
	Attorney Docket Number	DRF 3.3-054

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
WWI	1	97/10819	WO	A1	1997-03-27	Ligand Pharmaceuticals, Inc.		<input type="checkbox"/>
	2	97/37688	WO	A2	1997-10-16	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	3	97/41097	WO	A2	1997-11-06	Dr. Reddy's Research Foundation, et al.		<input type="checkbox"/>
	4	98/36755	WO	A1	1998-08-27	Warner Lambert Co.		<input type="checkbox"/>
	5	98/57635	WO	A1	1998-12-23	Smithkline Beecham PLC		<input type="checkbox"/>
↓	6	00/00195	WO	A1	2000-01-06	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10561639	
Filing Date	2005-12-20	
First Named Inventor	Karsten WASSERMANN	
Art Unit	1614	
Examiner Name	Zhang, Nancy L.	
Attorney Docket Number	DRF 3.3-054	

1/1/1	7	00/27434	WO	A1	2000-05-18	Smithkline Beecham PLC	<input type="checkbox"/>
	8	00/38666	WO	A2	2000-07-06	Metabasis Therapeutics, Inc.	<input type="checkbox"/>
	9	00/45818	WO	A1	2000-08-10	Astrazeneca UK Limited	<input type="checkbox"/>
	10	00/78333	WO	A2	2000-12-28	Eli Lilly and Company	<input type="checkbox"/>
	11	01/03659	WO	A1	2001-01-18	The Salk Institute for Biological Studies	<input type="checkbox"/>
	12	01/32158	WO	A2	2001-05-10	Bristol-Myers Squibb Company	<input type="checkbox"/>
	13	01/52825	WO	A2	2001-07-26	Novartis AG	<input type="checkbox"/>
	14	02/080936	WO	A1	2002-10-17	Ortho McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
	15	02/13864	WO	A1	2002-02-21	Sankyo Company Limited	<input type="checkbox"/>
	16	02/058732	WO	A2	2002-08-01	Schering Corporation	<input type="checkbox"/>
↓	17	02/072069	WO	A1	2002-09-19	Novo Nordisk A/S	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10561639
	Filing Date		2005-12-20
	First Named Inventor		Karsten WASSERMANN
	Art Unit		1614
	Examiner Name		Zhang, Nancy L.
	Attorney Docket Number		DRF 3.3-054

/WW/18	02/072146	WO	A2	2002-09-19	Novartis-Erfindungen Verwaltungsgesellschaft MBH		<input type="checkbox"/>
19							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	TS
/WW/	1	PAUL, MARTIN: "Modes of Action and Clinical Efficacy of Pioglitazone as a New Principle for the Treatment of Type 2 Diabetes," Arzneimittel-Forschung, Vol. 49, No. 10 (1999), pp. 835-842.	<input type="checkbox"/>
/WW/	2	REASNER, C. A., II: "Promising new approaches," DIABETES, OBESITY AND METABOLISM, Vol. 1, (Suppl. 1) (1999), pp. S41-S48	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	/Walter Webb/	Date Considered	09/24/2007
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.